Presenting at AHS 2022, researchers evaluated the safety and efficacy of eptinezumab for migraine in patients with episodic and chronic migraine with prior treatment failures.
Presenting at AHS 2022, researchers assessed the long-term safety and tolerability of atogepant, including the proportion of participants who sustained initial responses of 50% or greater, 75% or greater, or 100% reduction in MMDs over 12 and 52 weeks.
Presenting at AHS 2022, researchers summarized the outcomes of 3 patients with visual snow using noninvasive vagal nerve stimulation.
Presenting at AHS 2022, researchers sought to determine whether celecoxib was effective among patients with acute migraine with or without aura.
Presenting at AHS 2022, researchers examined the effects of supplementation of B vitamins and a combination of these vitamins on women with episodic migraine.
Presenting at AHS 2022, researchers assessed the efficacy of a 1-year treatment period with ubrogepant 50 or 100 mg in patients with migraine attacks with mild and moderate or severe pain.
Presenting at AHS 2022, researchers assessed the efficacy of galcanezumab 120 mg/month in the prevention of episodic migraine.
Presenting at AHS 2022, researchers evaluated the real-world effectiveness of ubrogepant in combination with onabotulinumtoxinA to treat breakthrough migraine.
Presenting at AHS 2022, researchers determined the effect of generalized anxiety disorder on the responsiveness of BoNT-A treatment from pediatric patients with chronic migraine.
Researchers sought to evaluate quality of life, disability, and functioning based on the use of preventative treatment and failure in patients with low-frequency and moderate- to high-frequency episodic migraine.
Researchers sought to assess the epidemiology of comorbid sleep disorders in patients with migraine.
Presenting at AHS 2022, researchers assessed the effect of a high-fat meal on the pharmacokinetics of immediate release atogepant tablets.